Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company reported a revenue of 11.76 billion yuan for H1 2024, representing a year-on-year growth of 9.9%, and a net profit attributable to shareholders of 800 million yuan, up 13.1% year-on-year. Despite a decline in profit growth among most listed companies in the industry, the company achieved positive profit growth due to its effective management capabilities [2] - The company continues to expand its store count, adding 1,575 stores in H1 2024, which is expected to drive long-term revenue growth. As of H1 2024, the total number of stores reached 14,736, including 3,426 franchise stores [3] - The company's gross margin for H1 2024 was 40.05%, a slight increase from the previous year, indicating strong product management capabilities. The net profit margin was 7.31%, maintaining a relatively high level in the industry [4] - The company has slightly adjusted its profit forecast for 2024-2026, expecting total revenues of 25.95 billion, 31.84 billion, and 37.68 billion yuan, with corresponding net profits of 1.62 billion, 1.99 billion, and 2.40 billion yuan [5] Summary by Sections Financial Performance - In H1 2024, the company achieved a revenue of 11.76 billion yuan, with a net profit of 800 million yuan, reflecting a growth of 9.9% and 13.1% respectively [2] - The Q2 revenue was 5.79 billion yuan, with a net profit of 390 million yuan, showing a year-on-year increase of 6.5% and 6.1% [2] Growth Potential - The company added 1,575 new stores in H1 2024, with a total of 14,736 stores by the end of the period, indicating a strong growth trajectory [3] - The company has a significant number of stores qualified as "medical insurance designated retail pharmacies," which is expected to enhance revenue through prescription outflow [3] Profitability - The gross margin for H1 2024 was 40.05%, with a net profit margin of 7.31%, both indicating strong profitability relative to industry standards [4] - The company is expected to maintain a high level of profitability due to its refined management and scale effects, despite potential pressures from industry competition [4] Earnings Forecast - The company has revised its earnings forecast, projecting revenues of 25.95 billion yuan in 2024, with net profits of 1.62 billion yuan, reflecting a growth rate of 14.90% [5]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 23.76 RMB [2][4] Core Views - The company achieved steady growth in both revenue and net profit in H1 2024, with revenue reaching 11.76 billion RMB (+9.9% YoY) and net profit attributable to shareholders of 800 million RMB (+13.1% YoY) [1] - The company's operating cash flow increased significantly by 29.4% YoY to 1.82 billion RMB, driven by organic growth, M&A, and franchise expansion [1] - The company's cost efficiency improved, with the sales expense ratio decreasing to 25.6% (-0.2 pct) and the management expense ratio dropping to 4.1% (-0.2 pct) [1] - The company's O2O business grew rapidly, with O2O sales reaching 880 million RMB (+26.3% YoY), and over 10,000 stores now offering O2O services [1] Store Expansion - The company added 1,575 new stores in H1 2024, including 842 self-built stores, 293 acquired stores, and 440 new franchise stores, resulting in a net increase of 1,486 stores [1] - As of H1 2024, the company operates a total of 14,736 stores, including 11,310 directly operated stores and 3,426 franchise stores [1] - 88.3% of the directly operated stores have obtained medical insurance retail qualifications, totaling 9,984 stores [1] Financial Forecasts - The report revised the company's revenue and gross margin forecasts for 2025, with adjusted net profit forecasts for 2024-2026 at 1.601 billion, 1.919 billion, and 2.263 billion RMB, respectively [2] - The company's revenue is expected to grow at a CAGR of 16.5% from 2024 to 2026, reaching 33.534 billion RMB by 2026 [3] - The net profit margin is projected to remain stable at around 6.5%-6.7% from 2024 to 2026 [3] Industry Trends - The retail pharmacy industry in China has seen increasing chain rates and market concentration, with the chain rate reaching 58.5% in 2023 [1] - The sales growth rate of the top 100 companies in the industry was 9.6% in 2023, significantly higher than the industry average of 2.9% [1] Valuation - The company's PE ratio is expected to decline from 18.3x in 2022 to 10.2x by 2026, reflecting strong earnings growth [3] - The EV/EBITDA ratio is projected to decrease from 8.2x in 2022 to 4.9x by 2026, indicating improving valuation metrics [8]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the stock in the near term [10]. Core Insights - The company has demonstrated steady revenue growth, with total revenue of 11.762 billion yuan in H1 2024, reflecting a year-on-year increase of 9.86%. The net profit attributable to shareholders reached 798 million yuan, up 13.13% year-on-year [10]. - The company is focusing on regional expansion, having opened 1,575 new stores during the reporting period, including 842 self-built stores and 293 acquired stores. The total number of chain pharmacies reached 14,736, a year-on-year increase of 27.25% [10]. - The retail business is developing steadily, with retail revenue of 10.398 billion yuan in H1 2024, a year-on-year increase of 8.32%. The gross margin for retail was 40.94% [10]. - The company is actively building a new retail system in the pharmaceutical sector, with a total membership of 96.16 million, a year-on-year growth of 23.84%. Membership sales accounted for 77% of total sales [10]. - The company is expected to see net profits of 1.740 billion yuan, 2.128 billion yuan, and 2.584 billion yuan for the years 2024, 2025, and 2026, respectively, with corresponding EPS of 1.43 yuan, 1.76 yuan, and 2.13 yuan [10]. Summary by Sections Financial Performance - In H1 2024, the company achieved total revenue of 11.762 billion yuan, a 9.86% increase year-on-year, and a net profit of 798 million yuan, up 13.13% [10]. - The gross margin for H1 2024 was 40.05%, with a net profit margin of 7.31% [10]. Store Expansion - The company opened 1,575 new stores in the reporting period, including 842 self-built and 293 acquired stores, resulting in a total of 14,736 chain pharmacies nationwide, a 27.25% increase year-on-year [10]. Business Segments - Retail revenue reached 10.398 billion yuan, growing 8.32% year-on-year, while wholesale revenue was 999 million yuan, increasing by 20.91% [10]. - The company’s high-margin traditional Chinese medicine segment saw significant growth, with revenue of 1.165 billion yuan, a 14.82% increase year-on-year [10]. Membership and New Retail Initiatives - The company has built a membership base of 96.16 million, a 23.84% increase year-on-year, with membership sales contributing 77% to total sales [10]. - Internet sales revenue reached 1.096 billion yuan, a 20.18% increase year-on-year, with O2O sales growing by 26.33% [10].

Investment Rating - The report maintains a "Buy-A" investment rating for the company, with a 6-month target price of 25.40 CNY per share [5][6]. Core Insights - The company achieved a revenue of 11.762 billion CNY in H1 2024, representing a year-on-year growth of 9.86%. The net profit attributable to shareholders after deducting non-recurring items was 786 million CNY, up 15.77% year-on-year [2][5]. - The growth in profits is attributed to both organic and external growth from store expansion, as well as improved management efficiency [2][3]. - The company continues to focus on a "regional focus and steady expansion" strategy, with a total of 14,736 stores as of H1 2024, marking a 27.25% increase compared to H1 2023 [3]. - The overall gross margin for H1 2024 was 40.05%, slightly up by 0.06 percentage points from the previous year, indicating stable profitability [4]. Summary by Sections Revenue and Profit Growth - In H1 2024, the company reported revenues of 117.62 billion CNY, with retail and wholesale segments contributing 103.98 billion CNY (+8.32%) and 9.97 billion CNY (+20.91%) respectively [2][5]. - The net profit attributable to shareholders after non-recurring items was 786 million CNY, reflecting a 15.77% increase year-on-year [2][5]. Store Expansion Strategy - The company has been actively expanding its store network, with 842 new self-built stores, 293 acquired stores, and 440 new franchise stores added in H1 2024 [3]. - The total number of stores reached 14,736, including 3,426 franchise stores, demonstrating a robust growth strategy [3]. Profitability and Management Efficiency - The company's gross margin stood at 40.05% in H1 2024, with specific margins for various product categories: 34.85% for Western and Chinese medicines, 48.74% for traditional Chinese medicine, and 51.10% for non-pharmaceutical products [4]. - Management efficiency improved, as evidenced by a decrease in sales and management expense ratios by 0.15 and 0.20 percentage points respectively [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company has achieved steady revenue and profit growth in H1 2024, with a revenue of 11.762 billion yuan (up 9.86% year-on-year) and a net profit attributable to shareholders of 798 million yuan (up 13.13% year-on-year) [5] - The company is focusing on regional expansion and steady growth, with a total of 14,736 stores as of H1 2024, including 3,426 franchise stores [7] - The company has adjusted its profit forecasts for 2024-2026, expecting net profits of 1.607 billion yuan, 1.906 billion yuan, and 2.297 billion yuan respectively [5] Financial Performance Summary - H1 2024 revenue: 117.62 billion yuan (up 9.86% year-on-year); Q2 2024 revenue: 57.91 billion yuan (up 6.45% year-on-year) [5] - H1 2024 gross margin: 40.05% (up 0.06 percentage points); net margin: 7.31% (down 0.15 percentage points) [5] - Retail business revenue: 103.98 billion yuan (up 8.32%); wholesale business revenue: 9.97 billion yuan (up 20.91%) [6] Business Expansion and Strategy - The company added 1,575 new stores in H1 2024, including 842 self-built stores and 440 franchise stores [7] - The company emphasizes refined, standardized, and systematic operational management, supported by a digital and intelligent management platform [7]

医药生物/医药商业 公 司 研 究 益丰药房（603939.SH） 2024 年 09 月 03 日 2024H1 营收利润稳健增长，门店扩张稳步推进 ——公司信息更新报告 投资评级：买入（维持） 日期 2024/9/2 余汝意（分析师） yuruyi@kysec.cn 证书编号：S0790523070002 开 源 证 券 证 券 研 究 报 告 公司信息更新报告 | --- | --- | |-------------------------|-------------| | | | | 当前股价 ( 元 ) | 18.44 | | 一年最高最低 ( 元 ) | 46.88/17.91 | | 总市值 ( 亿元 ) | 223.58 | | 流通市值 ( 亿元 ) | 223.08 | | 总股本 ( 亿股 ) | 12.12 | | 流通股本 ( 亿股 ) | 12.10 | | 近 3 个月换手率 (%) | 72.05 | 股价走势图 益丰药房 沪深300 -40% -20% 0% 20% 40% 60% 2023-09 2024-01 2024-05 数据来源：聚源 相关研究报告 《营收稳健增长， ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 11.762 billion yuan in H1 2024, representing a year-on-year increase of 9.86%, and a net profit attributable to shareholders of 798 million yuan, up 13.13% year-on-year [3] - The company continues to deepen its regional market presence through a strategy of "new openings + acquisitions + franchising," resulting in a total of 14,736 stores by H1 2024, with 1,575 new stores added since the beginning of the year [3] - The O2O business has shown remarkable growth, with online revenue reaching 1.096 billion yuan in H1 2024, a 20.18% increase, and O2O revenue specifically growing by 26.33% to 878 million yuan [3] Financial Performance Summary - Total revenue (in million yuan) for the years 2022A to 2026E is projected to grow from 19,886 to 33,042, with a CAGR of approximately 14.46% [2] - Net profit attributable to shareholders (in million yuan) is expected to rise from 1,262 in 2022A to 2,319 in 2026E, reflecting a growth rate of 19.59% [2] - The latest diluted EPS is projected to increase from 1.04 in 2022A to 1.91 in 2026E, indicating a strong upward trend in earnings per share [2] Business Segment Overview - Retail business revenue in H1 2024 was 10.398 billion yuan, up 8.32%, while wholesale business revenue reached 999 million yuan, a significant increase of 20.85% [3] - The gross margin for retail business was 40.94%, showing a slight increase, while the wholesale business gross margin was 9.57%, reflecting a decrease of 0.61 percentage points [3] - Revenue from traditional Chinese and Western medicine reached 8.878 billion yuan, with a gross margin of 34.85%, while non-pharmaceutical products generated 1.353 billion yuan with a gross margin of 51.10% [3] Store Expansion and Market Strategy - The company has expanded its store network significantly, with 1,135 new direct stores and 440 new franchise stores added in H1 2024 [3] - The company is focusing on consolidating its presence in the Central South, East China, and North China regions, with notable new store openings in these areas [3] - The O2O strategy is being enhanced through the integration of membership, big data, and online healthcare services, with over 10,000 stores now part of the O2O multi-channel platform [3]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2024-083 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于使用闲置募集资金委托理财到期赎回 并继续委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次赎回产品名称：招商银行点金系列看涨两层区间 29 天结构性存款 （2000 万）、利多多公司稳利 24JG3401 期(月月滚利 5 期)人民币对公结构性存 款（7700 万） 赎回金额：9,700.00 万元 | | | 二、 本次委托理财的情况 1、委托理财目的 在确保不变相改变募集资金用途与不影响募集资金投资项目正常运行的情 况下，提高闲置募集资金的使用效率，增加公司收益，降低财务成本。 本次继续委托理财金额：8,100.00 万元 已履行的审议程序：经公司第四届董事会第三十八次会议审议通过 特别风险提示：公司将对投资产品进行严格评估，尽管公司选择本金保障 类理财产品，但金融市 ...

证券研究报告 非金融公司|公司点评|益丰药房（603939） 业绩增长稳健，彰显经营韧性 请务必阅读报告末页的重要声明 glzqdatemark1 2024年09月03日 证券研究报告 |报告要点 公司发布 2024 年半年报，2024 年上半年实现收入 117.62 亿元，同比增长 9.86%；归母净利 润 7.98 亿元，同比增长 13.13%；扣非后归母净利润 7.86 亿元，同比增长 15.77%。公司坚持 "区域聚焦，稳健扩张"的发展战略，通过"新开+并购+加盟"的拓展模式，深耕中南、华东、华 北市场，截至 2024 年 6 月底，公司门店总数达 14,736 家（含加盟店 3,426 家），较 2023 年 底增加 1,486 家。 |分析师及联系人 郑薇 SAC：S0590521070002 请务必阅读报告末页的重要声明 1 / 5 非金融公司|公司点评 glzqdatemark2 2024年09月03日 益丰药房(603939) 业绩增长稳健，彰显经营韧性 | --- | --- | |----------------------------|-------------------| | | ...

Investment Rating - The report assigns a "Buy" rating for Yifeng Pharmacy (603939.SH) [1] Core Views - Yifeng Pharmacy achieved a revenue of 11.762 billion yuan in H1 2024, representing a year-on-year growth of 9.86%, and a net profit attributable to shareholders of 798 million yuan, up 13.13% from the previous year [1] - The company is focusing on balanced development and prioritizing efficiency amid industry competition [1] - The retail business gross margin for H1 2024 was 40.94%, slightly up by 0.06 percentage points compared to the same period in 2023 [1] - The company is expected to see revenue growth from 24.786 billion yuan in 2024 to 29.171 billion yuan in 2026, with net profits projected to rise from 1.614 billion yuan to 2.121 billion yuan in the same period [3][4] Summary by Sections Company Overview - Yifeng Pharmacy has maintained a net increase in store numbers despite industry challenges, with 1,575 new stores opened in H1 2024, including 842 self-built stores and 293 acquired stores [1] - The company is adapting to industry changes by enhancing management efficiency and adjusting store opening and closing strategies [1] Financial Performance - The company reported a gross margin of 40.94% in H1 2024, with drug gross margins at 36.46% (down 0.12 percentage points) and non-drug gross margins at 51.1% (up 0.03 percentage points) [1] - Forecasts indicate that the company's revenue will grow from 24.786 billion yuan in 2024 to 29.171 billion yuan in 2026, with corresponding net profits of 1.614 billion yuan and 2.121 billion yuan [3][4] Market Position - Yifeng Pharmacy is positioned as a leading player in the retail pharmacy sector, benefiting from the increasing concentration in the industry due to policy support [2] - The company operates the largest number of chain pharmacies among private pharmacy chains in China, with 14,736 stores as of June 2024 [1]